What do you think? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

What do you think?


Pharmaceutical Technology Europe
Volume 22, Issue 5


Fedra Pavlou
Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry. In each issue of PTE since February of this year, we have published some of the highlights from our research within the opening feature of each issue. They have then been published in full in PTE Digital; our new monthly digital magazine, designed to be downloaded, saved and archived, allowing you to create your own digital library of PTE special features.

We would welcome your thoughts on our new print and digital special feature articles; so please do feel free to contact me directly and let me know what you think.

Alternatively, you could communicate your opinions to me by taking part in our readership survey, which will be running within the coming weeks. PTE's annual readership surveys are designed to help us to understand your needs and to find out what we are doing well and how we can serve you better. So if you already receive our eNewsletter, then I encourage you to take part in our series of short surveys, which will be distributed over the course of several weeks and should take no more than 3 minutes of your time to complete. If you do not receive PTE's weekly eNewsletter and would like to be alerted once the surveys are available, then please feel free to sign up at http://www.pharmtech.com/signup.

For this month's special feature, we spoke with experts at some of the world's leading analytical equipment manufacturers to uncover some of the hurdles to good and consistent analysis and the exciting developments on the horizon.

Also this month, we take a look at one of the hot topics of the moment — pharma's move towards the emerging markets. While many immediately couple low manufacturing costs and a threat to western employment with pharma's growing interest in the emerging markets, this month's editorial discusses the problems of high disease prevalence and unmet need, specifically in China, and provides advice on how pharmaceutical companies should adapt their approach to R&D and commercialisation if they are to succeed in these rapidly expanding markets. It makes for interesting reading and hopefully brings you another perspective on the importance of these markets to the pharmaceutical industry.

Enjoy!

Fedra Pavlou

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here